See more : Cell Source, Inc. (CLCS) Income Statement Analysis – Financial Results
Complete financial analysis of Aurora Spine Corporation (ASAPF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aurora Spine Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
- AVEO Pharmaceuticals, Inc. (AVEO) Income Statement Analysis – Financial Results
- Beta Systems Software AG (BSS.F) Income Statement Analysis – Financial Results
- Gamma Communications plc (GAMCF) Income Statement Analysis – Financial Results
- McRae Industries, Inc. (MCRAB) Income Statement Analysis – Financial Results
- Medi-Caps Limited (MEDICAPQ.BO) Income Statement Analysis – Financial Results
Aurora Spine Corporation (ASAPF)
About Aurora Spine Corporation
Aurora Spine Corporation, through its subsidiary, Aurora Spine, Inc., engages in the development and distribution of minimally invasive interspinous fusion systems and devices in Canada. The company offers interspinous process lumbar fusion devices, such as the ZIP, ZIP ULTRA, ZIP LP, and ZIP-51 for patients suffering from degenerative disc diseases; and Ti-Coated polyether ether ketone interbody cages, which provide spacing and stability between the vertebrae while bone grows to complete the fusion process. It also provides sterile-packed titanium plasma spray coated spinal infusion implants for bone growth, as well as interbody products, such as EOS, VOX, Echo, Echo SD, and EchoXL for the lumbar section of the spine, and discovery for cervical procedures. In addition, the company provides SOLO, an anterior lumbar interbody fusion 3D printed stand-alone fusion device, which is an integrated plate and spacer system that helps to preserve the natural anatomic profile while providing spinal column support and stability; and SiLo, a posterior fusion device for the sacroiliac joint. Further, it offers DEXA-C, a cervical interbody system, which is a porous 3D-printed intervertebral body fusion device that incorporates low-, mid-, or high-density lattice pattern options to support the matching of patients' bone quality. Aurora Spine Corporation was incorporated in 2013 and is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.52M | 14.88M | 10.54M | 8.65M | 11.15M | 8.68M | 5.99M | 6.76M | 4.90M | 2.59M | 206.99K |
| Cost of Revenue | 6.31M | 7.07M | 5.71M | 5.18M | 7.61M | 4.09M | 3.43M | 3.37M | 2.21M | 1.14M | 82.80K |
| Gross Profit | 8.21M | 7.81M | 4.83M | 3.47M | 3.55M | 4.59M | 2.56M | 3.38M | 2.69M | 1.45M | 124.19K |
| Gross Profit Ratio | 56.55% | 52.49% | 45.84% | 40.12% | 31.81% | 52.90% | 42.73% | 50.08% | 54.91% | 56.04% | 60.00% |
| Research & Development | 1.11M | 1.16M | 941.30K | 286.25K | 207.55K | 36.30K | 21.06K | 40.41K | 78.12K | 280.69K | 158.19K |
| General & Administrative | 6.82M | 6.08M | 4.99M | 3.65M | 3.89M | 3.64M | 3.70M | 4.11M | 4.71M | 7.30M | 1.14M |
| Selling & Marketing | 722.29K | 1.05M | 799.93K | 106.01K | 138.92K | 47.14K | 31.86K | 91.43K | 287.68K | 1.00M | 140.28K |
| SG&A | 7.54M | 7.12M | 5.79M | 3.76M | 4.03M | 3.68M | 3.74M | 4.20M | 5.00M | 8.30M | 1.28M |
| Other Expenses | 0.00 | 868.59K | 648.69K | 589.54K | 386.65K | 780.56K | 984.11K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.66M | 9.15M | 7.38M | 4.63M | 4.63M | 4.50M | 4.74M | 5.00M | 5.81M | 8.96M | 1.45M |
| Cost & Expenses | 14.97M | 16.22M | 13.10M | 9.81M | 12.23M | 8.59M | 8.17M | 8.37M | 8.02M | 10.10M | 1.45M |
| Interest Income | 0.00 | 0.00 | 0.00 | 4.63K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 185.17K | 163.60K | 157.70K | 92.35K | 174.01K | 147.59K | 144.65K | 60.93K | 26.93K | 0.00 | 0.00 |
| Depreciation & Amortization | 1.05M | 834.17K | 642.98K | 620.68K | 395.64K | 740.76K | 855.88K | 752.84K | 750.81K | 385.82K | 3.80K |
| EBITDA | -446.20K | -450.68K | -1.54M | -686.23K | -709.74K | 816.09K | -1.35M | -869.19K | -2.00M | -7.15M | -3.40M |
| EBITDA Ratio | -3.07% | -2.74% | -18.03% | -6.64% | -6.21% | 10.04% | -22.62% | -12.67% | -52.56% | -274.90% | -696.43% |
| Operating Income | -446.20K | -1.34M | -2.55M | -1.16M | -1.08M | 91.44K | -2.18M | -1.68M | -3.12M | -7.51M | -1.45M |
| Operating Income Ratio | -3.07% | -9.03% | -24.19% | -13.46% | -9.68% | 1.05% | -36.42% | -24.85% | -63.70% | -289.79% | -698.27% |
| Total Other Income/Expenses | -1.23M | -158.06K | 191.04K | 931.31K | -174.79K | -159.64K | -59.30K | 0.00 | 205.32K | 0.00 | 0.00 |
| Income Before Tax | -1.68M | -1.50M | -2.36M | -232.09K | -1.25M | -68.20K | -2.24M | -1.68M | -2.92M | -7.51M | -1.45M |
| Income Before Tax Ratio | -11.57% | -10.09% | -22.37% | -2.68% | -11.25% | -0.79% | -37.41% | -24.85% | -59.51% | -289.79% | -698.27% |
| Income Tax Expense | 0.00 | 62.29K | 159.10K | 87.71K | 174.01K | 12.05K | -85.35K | 60.93K | -205.32K | 0.00 | 0.00 |
| Net Income | -1.68M | -1.56M | -2.52M | -319.80K | -1.43M | -80.25K | -2.16M | -1.68M | -2.92M | -7.51M | -1.45M |
| Net Income Ratio | -11.57% | -10.51% | -23.88% | -3.70% | -12.81% | -0.92% | -35.98% | -24.85% | -59.51% | -289.79% | -698.27% |
| EPS | -0.02 | -0.02 | -0.04 | -0.01 | -0.03 | 0.00 | -0.06 | -0.05 | -0.11 | -0.35 | -0.22 |
| EPS Diluted | -0.02 | -0.02 | -0.04 | -0.01 | -0.03 | 0.00 | -0.06 | -0.05 | -0.11 | -0.35 | -0.22 |
| Weighted Avg Shares Out | 70.67M | 66.80M | 58.71M | 54.63M | 46.46M | 42.15M | 35.18M | 32.22M | 25.95M | 21.62M | 6.58M |
| Weighted Avg Shares Out (Dil) | 70.67M | 66.80M | 58.71M | 54.63M | 46.46M | 42.15M | 35.18M | 32.22M | 25.95M | 21.62M | 6.58M |
Aurora Spine Corporation Schedules Conference Call to Update Investors and Discuss First Quarter Fiscal Year 2024 Financial Results
Aurora Spine Corporation Announces Fourth Quarter and Fiscal 2023 Financial Results
Aurora Spine Corporation Celebrates Second Anniversary of Initial Implantation of the World's First Bone Density Matched DEXA-C Cervical Interbody Fusion Device
Aurora Spine's Second Patent Related to DEXA Technology™ Patient-Matched Implant Technology Issued by the United States Patent Office
The United States Patent Office Grants New Patent for Aurora Spine's Translucent GhostTube™ Surgical Operating Tube
AURORA SPINE ANNOUNCES ATTENDANCE AT NORTH AMERICAN NEUROMODULATION SOCIETY (NANS) ANNUAL MEETING
Aurora Spine Announces Attendance at J.P. Morgan Healthcare Conference
Aurora Spine Corporation Announces Newly Published Paper on First 6-month Clinical Evaluation of its ZIP™ Fusion Implant
Aurora Spine Grants Stock Options
Aurora Spine Corporation Announces Third Quarter Fiscal 2023 Financial Results
Source: https://incomestatements.info
Category: Stock Reports